Expert Opinion on Drug Safety

Papers
(The H4-Index of Expert Opinion on Drug Safety is 24. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)
ArticleCitations
Update on weight-gain caused by antipsychotics: a systematic review and meta-analysis118
Neurologic complications of immune checkpoint inhibitors77
Safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma: a systematic review and meta-analysis62
Tackling antimicrobial resistance across sub-Saharan Africa: current challenges and implications for the future46
Biologics in the treatment of pustular psoriasis39
Newer formulations of intravenous iron: a review of their chemistry and key safety aspects – hypersensitivity, hypophosphatemia, and cardiovascular safety38
Interventions to improve spontaneous adverse drug reaction reporting by healthcare professionals and patients: systematic review and meta-analysis36
An overview of statin-induced myopathy and perspectives for the future36
Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part II: focus on elderly patients35
A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for baricitinib35
Up-to-date expert opinion on the safety of recently developed antipsychotics33
Gastrointestinal and cardiovascular adverse events associated with NSAIDs32
Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part I: focus on pediatric patients32
Thromboembolic events in younger women exposed to Pfizer-BioNTech or Moderna COVID-19 vaccines31
A safety evaluation of aripiprazole in the treatment of schizophrenia29
Inclisiran: a small interfering RNA strategy targeting PCSK9 to treat hypercholesterolemia28
Adverse events related to topical drug treatments for acne vulgaris27
Tocilizumab in COVID-19: a study of adverse drug events reported in the WHO database26
CGRP inhibitors for migraine prophylaxis: a safety review26
Safety profile of ocrelizumab for the treatment of multiple sclerosis: a systematic review26
A real-world pharmacovigilance study of axitinib: data mining of the public version of FDA adverse event reporting system26
Vitiligo induced by immune checkpoint inhibitors in melanoma patients: an expert opinion25
Long-term safety of ketamine and esketamine in treatment of depression24
Efficacy and safety of racemic ketamine and esketamine for depression: a systematic review and meta-analysis24
Use of medications during pregnancy and breastfeeding for Crohn’s disease and ulcerative colitis24
0.0295729637146